Lactococcus lactis CCFM1018 Adsorption of DEHP Plasticizer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for mitigating the toxicity of di(2-ethylhexyl) phthalate (DEHP) and its metabolite mono(2-ethylhexyl) phthalate (MEHP) are inadequate, as existing probiotics have low adsorption rates and require high doses of antioxidant substances, which can cause side effects and fail to reduce body residue effectively.
Innovation Solution
Lactococcus lactis subsp. lactis CCFM1018 is developed, which has a high adsorption capacity for DEHP and MEHP, promoting their excretion from the body and reducing serum levels, thereby minimizing tissue damage, and is used in fermented products and pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing probiotics are used to adsorb DEHP, then some adsorption effect is achieved, but the adsorption rate is low (maximum 9.62%)
Solution Approach 1:
The patent applies parameter changes by modifying the surface properties of Lactococcus lactis through cultural conditions optimization. The strain was cultured under specific conditions (MRS medium, 37°C, 12-16 hours) to maximize cell surface area and adsorption sites, achieving a DEHP adsorption rate of 58.90%, which is significantly higher than existing probiotics.
Solution Approach 2:
The patent uses Lactococcus lactis as a model probiotic system, building upon known probiotic mechanisms while creating a superior version. The strain CCFM1018 serves as an optimized copy that replicates and enhances the natural adsorption capabilities of probiotics for plasticizer detoxification.
2Object-affected harmful factors
If high doses of antioxidant substances are taken to alleviate DEHP toxicity, then toxic effects are reduced, but side effects occur and body residue is not reduced
Solution Approach 1:
The patent converts the harmful DEHP plasticizer into a beneficial situation by using Lactococcus lactis to adsorb and eliminate it through the digestive system. The probiotic transforms the toxic substance problem into a beneficial excretion process, achieving detoxification without introducing harmful side effects from high-dose antioxidants.
Solution Approach 2:
Lactococcus lactis serves as an intermediary between DEHP toxicity and the human body. The probiotic acts as a mediator that binds to DEHP in the gut, preventing its absorption and facilitating its excretion, thereby protecting the body from toxic effects without requiring direct intervention from antioxidant substances.
3Quantity of substance
If Lactococcus lactis CCFM1018 is used to adsorb DEHP, then adsorption capacity is significantly improved, but further enhancement is needed to fully eliminate body residue
Solution Approach 1:
The patent applies preliminary action by having Lactococcus lactis CCFM1018 adsorb DEHP in the gastrointestinal tract before the plasticizer can be absorbed into the bloodstream and accumulated in body tissues. This preemptive binding prevents DEHP from entering systemic circulation, thereby eliminating body residue accumulation.
Solution Approach 2:
The patent optimizes multiple parameters including bacterial cell concentration, culture time, and incubation conditions to maximize adsorption capacity. By adjusting these parameters, the system achieves enhanced DEHP binding efficiency that effectively reduces body residue levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Lactococcus lactis subsp. lactis CCFM1018 significantly reduces DEHP and MEHP content in serum and increases their excretion in feces, effectively alleviating tissue damage without toxic side effects, outperforming other probiotics in adsorption capacity and efficacy.
Implementation Method 1
Lactococcus lactis subsp. lactis CCFM1018 has a high adsorption capacity for DEHP and MEHP
Data Source
AI summary
The disclosure discloses Lactococcus lactis subsp. lactis CCFM1018 and application thereof in preparation of food and medicine for excreting a plasticizer, and belongs to the technical field of microorganisms. The Lactococcus lactis subsp. lactis CCFM1018 not only is significantly better than the intestinal resident bacteria Escherichia coli and Enterococcus faecalis in terms of the effect of promoting the excretion of DEHP and MEHP, but also is better than the commercial strain Lactobacillus rhamnosus LGG. Therefore, the Lactococcus lactis subsp. lactis CCFM1018 of the disclosure can be used as an effective means to prevent and alleviate body damage caused by DEHP and MEHP, and does not have toxic or side effects of drugs. Lactococcus lactis subsp. lactis CCFM1018 can be used to prepare pharmaceutical compositions and fermented food for alleviating and preventing the toxicity of DEHP and metabolites thereof, and has a very broad application prospect.